Relenza
(Zanamivir)Phase 3Small molecule
Relenza is one of 62 small molecule programs targeting Endothelial Dysfunction. It is currently in Phase 3.
3
Indications
13
Total Trials
3
Active Trials
61
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Relenza
GGlaxo Dba Glaxosmithkline
Phase 3
Fluzone
SanofiPreclinical
Crestor
AstraZenecaPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Fluvirin
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Influenza6 trials
Swine Influenza1 trial
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
Terminated·—·Phase 3·NCT00979667·4 enrolled
Tics1 trial
Intravenous1 trial
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00921726·17 enrolled
Regulatory
FDA Approval Timeline[4]
Jul 26, 1999
RELENZA
NDA NDA021036
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zanamivir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGlaxo Dba Glaxosmithkline